Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: Results from a randomized phase III study

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 6, 2014, Pages 790-798

  Papp, K A ^a   Sundaram, M ^b   Bao, Y ^b   Williams, D A ^b   Gu, Y ^b   Signorovitch, J E ^c   Wang, Y ^b   Valdes, J M ^b   Mulani, P M ^b  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b ABBVIE INC   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIAKINUMAB; PLACEBO; MONOCLONAL ANTIBODY;

ACTIVITY IMPAIRMENT QUESTIONNAIRE; ARTICLE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT SCORE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; VISUAL ANALOG SCALE; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PRODUCTIVITY; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL; EFFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84900485940     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12177     Document Type: Article

References (43)

1. Menter A, Gottlieb A, Feldman SR, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
2. Raychaudhuri SP, Farber EM,. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15: 16-17.
3. Finlay AY, Coles EC,. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-244.
4. Krueger G, Koo J, Lebwohl M, et al,. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
5. de Korte J, Sprangers MA, Mombers FM, Bos JD,. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-147.
6. Revicki DA, Willian MK, Menter A, et al,. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007; 18: 341-350.
7. Schmitt JM, Ford DE,. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102-110.
8. Pearce DJ, Singh S, Balkrishnan R, et al,. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006; 17: 24-28.
9. Rapp SR, Feldman SR, Exum ML, et al,. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41 (3 Pt 1): 401-407.
10. Stahl E, Lindberg A, Jansson SA, et al,. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56.
11. Xie J, Wu EQ, Zheng ZJ, et al,. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke 2006; 37: 2567-2572.
12. Lillegraven S, Kvien TK,. Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 827-840.
13. Stein KR, Pearce DJ, Feldman SR,. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005; 24: 52-57.
14. Dauden E, Griffiths CE, Ortonne JP, et al,. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23: 1374-1382.
15. Nestle FO, Conrad C,. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J Invest Dermatol 2004; 123: xiv-xv.
16. Wilson NJ, Boniface K, Chan JR, et al,. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957.
17. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al,. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-1211.
18. Oppmann B, Lesley R, Blom B, et al,. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
19. Kimball AB, Gordon KB, Langley RG, et al,. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144: 200-207.
20. Gordon KB, Langley RG, Gottlieb AB, et al,. A phase III, randomized, controlled trial of the fully human IL-12/23 mAB briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012; 132: 304-314.
21. Gottlieb AB, Leonardi C, Kerdel F, et al,. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 652-660.
22. Strober BE, Crowley JJ, Yamauchi PS, et al,. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 661-668.
23. Reich K, Langley RG, Papp KA, et al,. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365: 1586-1596.
24. Ryan C, Leonardi CL, Krueger JG, et al,. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306: 864-871.
25. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
26. Badia X, Mascaro JM, Lozano R,. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol 1999; 141: 698-702.
27. Shikiar R, Bresnahan BW, Stone SP, et al,. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53.
28. Lewis V, Finlay AY,. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169-180.
29. Shikiar R, Willian MK, Okun MM, et al,. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
30. Gottlieb AB, Matheson RT, Lowe N, et al,. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632.
31. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
32. Feldman SR, Gordon KB, Bala M, et al,. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005; 152: 954-960.
33. Ortonne JP, Shear N, Shumack S, Henninger E,. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 2005; 5: 13.
34. Revicki D, Willian MK, Saurat JH, et al,. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-557.
35. Ware J, Kosinski M, Keller S,. SF-36 Physical and Mental Health Summary Scales: A user's manual. The Health Institute, New England Medical Center, Boston, 1994.
36. Finlay AY, Salek MS, Haney J,. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206: 307-315.
37. Feldman SR, Menter A, Koo JY,. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150: 317-326.
38. Reilly MC, Zbrozek AS, Dukes EM,. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-365.
39. Reich K, Nestle FO, Papp K, et al,. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006; 154: 1161-1168.
40. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
41. Krueger GG, Langley RG, Finlay AY, et al,. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005; 153: 1192-1199.
42. Lebwohl M, Papp K, Han C, et al,. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-146.
43. Kimball AB, Yu AP, Signorovitch J, et al,. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 2012; 66: e67-e76.